Latest News

Pertuzumab retreatment modestly improved progression-free survival and meaningfully improved overall survival in advanced nHER2–positive breast cancer.
Retreatment With Pertuzumab/T-DM1 Improves PFS in HER2+ Breast Cancer

February 12th 2025

Pertuzumab retreatment modestly improved progression-free survival and meaningfully improved overall survival in advanced nHER2–positive breast cancer.

Findings from the ICE3 trial revealed that no serious adverse effects were experienced related to the use of cryoablation in ipsilateral breast tumors.
Breast Cryoablation Inhibits Recurrence, Enhances Survival in Breast Cancer

February 11th 2025

Managing Brain Metastases in Patients with HER2+ Metastatic Breast Cancer
Managing Brain Metastases in Patients with HER2+ Metastatic Breast Cancer

February 9th 2025

Risk model data may provide reassurance for individuals undergoing hormone therapy with an already heightened breast cancer risk due to family history.
Hormone Therapy Confers Modest Breast Cancer Risk Even With Family History

February 8th 2025

The safety profile of pembrolizumab plus neoadjuvant chemotherapy was consistent with the known profiles for each treatment.
Pembrolizumab Combo Enhances Response Rate in ER+/HER2– Breast Cancer

February 5th 2025

More News